HCW9302 for Alopecia Areata
This study is testing a new treatment called HCW9302, an IL-2 fusion protein, for people with Alopecia Areata (AA). HCW9302 is given by injection. The main goals are to see how safe HCW9302 is and to find the best dose for future studies. Researchers will be looking for any side effects and determining the recommended dose for a Phase 2 study. You may be able to join if you are an adult between 18 and 70 years old with a diagnosis of Alopecia Areata, including severe forms like totalis or universalis. The study plans to enroll about 30 participants.
- Study design
- This is a Phase 1, open-label study, meaning both you and the study team will know which treatment you are receiving. It involves a small number of participants (30 planned) and will test different doses of HCW9302.
- What's involved
- The study involves receiving HCW9302 by injection. Initially, you may receive a single dose, and later stages might involve multiple doses given every 28 days for four treatments.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary safety and dosing information will be measured at 9 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
At a glance
Conditions
Where it's being run
3 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Events (TEAEs) in Subjects Receiving HCW9302 Monotherapy9 Weeks
Evaluate the safety profile of HCW9302 monotherapy in subjects with Alopecia Areata (AA), based on the incidence, type, and severity of adverse events (AEs) classified according to MedDRA.
- Designate the recommended Phase 2 dose level (RP2D) for Phase 2 study of HCW9302 in subjects with AA9 Weeks